Clinical trial · no report yet · Phase 1
STELLAR-002
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- NCT05176483 ↗
- Recruiting
- Exelixis
- 45 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 25 | |
| Podcasts | 10 | |
| YouTube | 9 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC); Solid Tumor; Hepatocellular Carcinoma (HCC); Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Head and Neck Squamous Cell Carcinoma (HNSCC); Clear Cell Renal Cell Carcinoma (ccRCC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib; Nivolumab; Ipilimumab; Nivolumab + Relatlimab; Prednisone; Docetaxel; DDI Probe Cocktail
- Arms
- Zanzalintinib + Nivolumab Dose-Escalation Cohorts · Experimental
- Zanzalintinib + Nivolumab + Ipilimumab Dose-Escalation Cohorts · Experimental
- Zanzalintinib + Nivolumab Expansion Cohorts · Experimental
- Zanzalintinib + Nivolumab + Ipilimumab Expansion Cohorts · Experimental
- Zanzalintinib Single-Agent Expansion Cohorts · Experimental
- Zanzalintinib + Nivolumab + Relatlimab Dose-Escalation Cohorts · Experimental
- Zanzalintinib + Nivolumab + Relatlimab Expansion Cohorts · Experimental
- Zanzalintinib + Docetaxel + Prednisone Dose Expansion Cohort · Experimental
- Zanzalintinib + DDI Probe Substrates Dose Expansion Cohort · Experimental
- Enrollment
- 1,394 (estimated)
- Primary outcomes
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs)
- Expansion Stage (All Cohorts Except Cohort 15 [mCRPC, post-ARPI, visceral metastases] and Cohort 16 [DDI]): Objective Response Rate (ORR)
- Expansion Stage Cohort 3 (mCRPC, post 1 NHT): Progression-Free Survival (PFS)
- Expansion Stage Cohort 10 (CRC): Overall Survival (OS)
- Expansion Stage Cohort 15 (mCRPC, Post-ARPI, Visceral Metastases): PFS-6 (Six Month PFS)
- Expansion Stage Cohort 16 (DDI): Area Under the Concentration-Versus-Time Curve (AUC) of Each DDI Probe Substrate With and Without Zanzalintinib
- Expansion Stage Cohort 16 (DDI): Maximum Concentration (Cmax) of Each DDI Probe Substrate With and Without Zanzalintinib
- Sponsor
- Exelixis
- Start
- Dec 14, 2021
- Primary completion
- Jan 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05176483 · updated Oct 1, 2026